EGFR kinase inhibitors (Fudan University)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameEGFR kinase inhibitors (Fudan University)
Drug Alias Nameazaspirocycle/azetidine substituted 4-anilinoquinazoline derivatives
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesFudan University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFudan University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A